TROP2抗体-药物偶联物能治疗乳腺上皮-肌上皮癌吗？

IF 2.8 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.2147/OTT.S540295

Qing Zhao, Xiao Luo, Hua Xing, Chengwei Jiang, Jingchao Ma, Lu Tang

{"title":"TROP2抗体-药物偶联物能治疗乳腺上皮-肌上皮癌吗？","authors":"Qing Zhao, Xiao Luo, Hua Xing, Chengwei Jiang, Jingchao Ma, Lu Tang","doi":"10.2147/OTT.S540295","DOIUrl":null,"url":null,"abstract":"Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"18 ","pages":"1013-1025"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439690/pdf/","citationCount":"0","resultStr":"{\"title\":\"Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?\",\"authors\":\"Qing Zhao, Xiao Luo, Hua Xing, Chengwei Jiang, Jingchao Ma, Lu Tang\",\"doi\":\"10.2147/OTT.S540295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.\",\"PeriodicalId\":19534,\"journal\":{\"name\":\"OncoTargets and therapy\",\"volume\":\"18 \",\"pages\":\"1013-1025\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439690/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"OncoTargets and therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/OTT.S540295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S540295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

乳腺上皮-肌上皮癌（EMC）是一种罕见的由恶性上皮和肌上皮成分混合组成的双相肿瘤。乳腺上皮性肌上皮癌因其罕见，缺乏治疗策略，目前仍以局部治疗为主。我们在此报告一例乳腺上皮-肌上皮癌，患者为一33岁女性，接受保乳手术、前哨淋巴结活检、辅助化疗和放疗，并伴有快速肝和肺转移。转移灶射频消融治疗后，先后给予长春瑞滨联合顺铂和TROP2抗体药物偶联（ADC）治疗。在短暂的改善之后，出现了耐药性，疾病继续发展。患者死亡时PFS为5.6个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

查看原文本刊更多论文

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.